Neogen is set to report its fiscal Q1 earnings on October 6, 2026, with analysts expecting an adjusted EPS of $0.05 and slightly lower revenue around $208 million. The company faces regulatory pressure after the FDA issued a warning letter about contamination in its Neogen Vet HYCOAT product, linked to serious infections and at least 20 horse deaths. This FDA action adds risk for investors as the company navigates both earnings results and regulatory scrutiny. Neogen's financial ratios show moderate debt and strong liquidity, but earnings remain negative on a trailing basis.
Neogen's upcoming earnings and FDA warning provide context for health sector performance on Pluang. As of Oct 02, 2026 03:12 WIB, only 13 of 100 health-sector stocks rose while 86 fell. Among notable movers, ClearPoint Neuro Inc (CLPT) dropped 5.90% to USD 11.49 with a typical hold time of 9 days and 100% buy order activity, contrasting with American Well Corp (AMWL) at USD 12.79 down 5.82% over a longer 61-day hold time, and Adaptive Biotechnologies Corp (ADPT) at USD 27.27 down 5.66% with a 36-day hold and 100% buy orders.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
